- All
- Product Name
- Product Keyword
- Product Model
- Product Summary
- Product Description
- Multi Field Search
 |
151266-23-8
C5H4IN5
261.02
2.92±0.1
99% min (HPLC)
Yellow Solid
Cholangiocarcinoma
Futibatinib
11/05/2039 (Futibatinib)
FGFR
N
70 kg
40 t
2017
ISO 9001
Supply Chain
As of August 19, 2024, there are 163 potential suppliers manufacturing Futibatinib intermediate (R)-1-N-Boc-3-hydroxypyrrolidine (CAS No. 151266-23-8), including 27 factories and 23 labs, among which:
- The 25th percentile has an average registered capital of 1 million CNY;
- The 50th percentile has an average registerd capital of 3 million CNY;
- The 75th percentile has an average registered capital of 5 million CNY.
Feeling overwhelmed? Contact Unibest if you need us to quality-check other sources to strengthen your supply chain or to find a tailored solution for your specific procurement request.
Usage and ROS Analysis
Structure of Futibatinib
There are three distinct moieties of Futibatinib:
a pyrrolidine
a pyrazolo[3,4-d]pyrimidine
1-ethynyl-3,5-dimethoxybenzene
From the above synthesis map, the three key moieties correspond to the following Futibatinib intermediates
a pyrrolidine: CAS No. 109431-87-0
a pyrazolo[3,4-d]pyrimidine: CAS No. 151266-23-8
1-ethynyl-3,5-dimethoxybenzene: CAS No. 171290-52-1
For this particular Futibatinib intermediate, 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine, CAS No. 151266-23-8, is the bridge connecting other two pieces. The reaction sites are the iodine atom and the secondary amine.
Recommended Source
Unibest has commissioned our partners to develop Futibatinib intermediates for our long term generic developer clients, and their capacity can reach up to tons.
This particular Futibatinib intermediate, 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine, CAS No. 151266-23-8, has a wide synthetic application in pharmaceuticals. Apart from the use in Futibatinib synthesis, it can be used for Ibrutinib synthesis as well. Our partner first produced this compound in 2017, with a batch size of 300 to 500 kg.
